| P&L Statement | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 103 | 95 | 88 |
| Cost of Material Consumed | 68 | 70 | 68 |
| Change in Inventory | 9.5 | -2 | -0.5 |
| Gross Margins | 24.76 | 28.42 | 23.3 |
| Employee Benefit Expenses | 23 | 19 | 18 |
| Other Expenses | 43 | 19 | 19 |
| EBITDA | -40.5 | -11 | -16.5 |
| OPM | -39.32 | -11.58 | -18.75 |
| Other Income | 299 | 5 | 30 |
| Finance Cost | 3 | 2 | 2 |
| D&A | 3.3 | 3 | 3 |
| EBIT | -43.8 | -14 | -19.5 |
| EBIT Margins | -42.52 | -14.74 | -22.16 |
| PBT | 251 | -12 | 8 |
| PBT Margins | 243.69 | -12.63 | 9.09 |
| Tax | 60 | 0 | 0 |
| PAT | 191 | -12 | 8 |
| NPM | 185.44 | -12.63 | 9.09 |
| EPS | 1480.62 | -97.56 | 70.8 |
| Financial Ratios | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Profit Margin | -39.32 | -11.58 | -18.75 |
| Net Profit Margin | 185.44 | -12.63 | 9.09 |
| Earning Per Share (Diluted) | 1480.62 | -97.56 | 70.8 |
| Assets | 2023 | 2024 | 2025 |
|---|---|---|---|
| Fixed Assets | 13 | 16 | 22 |
| CWIP | 0 | 0 | 0 |
| Investments | 0.2 | 0.5 | 0.4 |
| Trade Receivables | 59 | 42 | 32 |
| Inventory | 9 | 12 | 11.5 |
| Other Assets | 191.8 | 149.5 | 126.1 |
| Total Assets | 273 | 220 | 192 |
| Liabilities | 2023 | 2024 | 2025 |
|---|---|---|---|
| Share Capital | 1.29 | 1.23 | 1.13 |
| FV | 10 | 10 | 10 |
| Reserves | 207 | 170 | 124 |
| Borrowings | 26 | 9 | 19 |
| Trade Payables | 19 | 21 | 28 |
| Other Liabilities | 19.71 | 18.77 | 19.87 |
| Total Liabilities | 273 | 220 | 192 |
| Cash-Flow Statement | 2023 | 2024 | 2025 |
|---|---|---|---|
| PBT | 251 | -12 | 8 |
| OPBWC | 253 | -11 | -16 |
| Change in Receivables | -25 | 17 | 10 |
| Change in Inventories | 24 | -3 | 0.1 |
| Change in Payables | -3 | 1.5 | 8 |
| Other Changes | -4 | -5.56 | 0.9 |
| Working Capital Change | -8 | 9.94 | 19 |
| Cash Generated From Operations | 24 | -1.06 | 3 |
| Tax | -60 | 1 | -1 |
| Cash Flow From Operations | 185 | -0.06 | 2 |
| Purchase of PPE | -3 | -4 | -9 |
| Sale of PPE | 0 | 1 | 0.2 |
| Cash Flow From Investment | -170 | 41 | 45 |
| Borrowing | -9 | -17 | -10 |
| Dividend | 0 | -2.5 | -0.19 |
| Equity | 0 | -22.5 | -53 |
| Others From Financing | -3 | -5 | 17.19 |
| Cash Flow from Financing | -12 | -47 | -46 |
| Net Cash Generated | 3 | -6.06 | 1 |
| Cash at the Start | 0.2 | 3 | 0.09 |
| Cash at the End | 3.2 | -3.06 | 1.09 |
Anglo?French Drugs & Industries Ltd (AFDIL), incorporated on 1 February 1923 and headquartered in Bengaluru, Karnataka, is one of India’s older pharmaceutical players.(The Company Check) The company began with the vision to help make India self-sufficient in key pharmaceutical formulations and over time expanded its manufacturing capability. AFDIL is reported to have marketed more than 300 products across various therapeutic segments including vitamins, sleep disorders, anti-epileptics, antioxidants and respiratory drugs, and has built a presence in about 16 countries across Eastern Europe, South East Asia and Africa.(Wealth Wisdom)
From a financial and shareholding perspective, AFDIL has undergone some transition and presented mixed signals. For the financial year ending 31 March 2025, AFDIL reported revenue from operations of around ?87.79 crore, slightly down from ?95.20 crore the previous year, yet it turned around from a loss to a net profit of approximately ?7.22 crore.(Capital Market) Shareholding data indicates that promoters hold roughly 64.8% of the equity while the public holds about 35.2%.(Wealth Wisdom) Although some sources describe AFDIL as unlisted, its equity shares were admitted to dealings on the Metropolitan Stock Exchange of India (MSEI) as of January 4 2018. For investors considering AFDIL’s unlisted shares or trading in its equity, key considerations include limited liquidity typical of small-cap or formerly unlisted entities, the impact of a legacy & niche product portfolio in a rapidly evolving Indian pharma market, and the fact that the company divested a portfolio of brands to Lupin Ltd in 2022 for about ?325 crore, which may affect future growth dynamics.(economictimes.indiatimes.com)
If you like, I can check recent share transactions, estimated value of the unlisted equity and peer company comparisons. Would you like me to pull that?
Q1: What is the first step to buy Anglo-French Drugs & Industries Ltd Unlisted Shares?
A1: The first step is to confirm your booking of Anglo-French Drugs & Industries Ltd Unlisted Shares with us at the agreed-upon trading price.
Q2: What documents are required to purchase these unlisted shares?
A2: You need to provide your Client Master Report (CMR) along with your PAN Card. If you are not transferring funds from the bank account mentioned in your CMR, you will also need to provide a Cancelled Cheque.
Q3: Why are these specific documents (CMR, PAN, Cancelled Cheque) required?
A3: These documents are required as part of the Know Your Customer (KYC) regulations mandated by SEBI.
Q4: What if I don't have a Client Master Report (CMR)?
A4: If you do not have a Client Master Report (CMR), you should contact your broker to obtain it.
Q5: How will I receive the bank details for payment?
A5: Once the initial steps are completed, we will provide you with the necessary bank details for the fund transfer.
Q6: What payment methods are accepted for buying the shares?
A6: Payments must be made via RTGS, NEFT, IMPS, or Cheque Transfer.
Q7: Are cash deposits allowed for payment?
A7: No, cash deposits are strictly not allowed. Payment must be made using RTGS, NEFT, IMPS, or Cheque Transfer.
Q8: From which bank account should I transfer the funds?
A8: Payment must be made from the same bank account in which the shares are intended to be credited.
Q9: What is the significance of transferring funds from the same account where shares will be credited?
A9: This is a regulatory requirement to ensure transparency and compliance with SEBI guidelines, linking the source of funds to the beneficiary account for the shares.
Q10: What is a "trading price" mentioned in the first step?
A10: The "trading price" refers to the agreed-upon price per share at which you will purchase the Anglo-French Drugs & Industries Ltd Unlisted Shares.
---